• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $MDT

    Medtronic plc.

    Subscribe to $MDT
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.

    IPO Year:

    Exchange: NYSE

    Website: medtronic.com

    Peers

    $ISRG
    $BAX
    $BDX
    $BSX
    $CAH
    $DHR
    $EW
    $IQV
    $SYK

    Recent Analyst Ratings for Medtronic plc.

    DatePrice TargetRatingAnalyst
    3/4/2025$92.00 → $107.00Neutral → Buy
    Citigroup
    10/10/2024$98.00 → $105.00Sector Perform → Outperform
    RBC Capital Mkts
    8/21/2024$92.00 → $94.00Perform
    Oppenheimer
    8/15/2024$76.00 → $90.00Sell → Neutral
    UBS
    8/14/2024$100.00 → $85.00Buy → Hold
    Stifel
    5/30/2024$83.00Sell
    Goldman
    7/19/2023$90.00Neutral
    Robert W. Baird
    6/30/2023$106.00Buy
    CL King
    5/30/2023$104.00Equal-Weight → Overweight
    Morgan Stanley
    4/24/2023$77.00 → $100.00Equal Weight → Overweight
    Wells Fargo
    See more ratings

    Medtronic plc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

      Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation GALWAY, Ireland, May 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2025 (FY25), which ended April 25, 2025. Q4 Key Highlights Q4 revenue of $8.9 billion increased 3.9% as reported and 5.4% organicQ4 GAAP diluted EPS of $0.82 increased 67%; non-GAAP diluted EPS of $1.62 increased 11%Q4 operating margin increased 380 basis points; Q4 non-GAAP operating margin increased 90 basis pointsQ4 operating pro

      5/21/25 6:45:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic announces intent to separate Diabetes business

      Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only company with a complete ecosystem to address intensive insulin management GALWAY, Ireland, May 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced its intent to separate its Diabetes business into a new standalone company ("New Diabetes Company"). This strategic decision for both Medtronic and New Diabetes Company will create a more focused Medtronic, with a more simplified portfolio in high margin growth markets. At the same time, it will cr

      5/21/25 6:44:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

      FDA Breakthrough Device Designation Awarded to AVIM Therapy FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch NEW HOPE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the first quarter ended March 31, 2025, and provided a business update highlighting continued regulatory momentum, disciplined operational execution, and a strengthening clinical development pipeline. Q1 2025 Highlights: U.S. Food and Drug Administration ("FDA") Breakthrough Device Design

      5/12/25 4:28:21 PM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products
    • Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

      GALWAY, Ireland, May 7, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2025 on Wednesday, May 21, 2025. A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https://news.medtronic.com. The news release will include summary financial information for the company's fourth quarter and full fiscal year 2025, which ended on Friday, April 25, 2025. Medtronic will host a video webcast at 7:00 a.m. CDT on May 21, 2025, to discuss results for its fourth quarter and full fiscal year 2025. The webcast can be a

      5/7/25 6:07:00 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

      Star Jones, award winning television personality & women's heart health advocate, helps kick off heart health conversations this Mother's Day with the Medtronic 'Letter to My Mother' campaign GALWAY, Ireland, May 7, 2025 /PRNewswire/ -- A new Medtronic-sponsored survey of women ages 30-50 reveals a significant gap in awareness and discussion around heart health among women and their mother-figures. Despite cardiovascular disease being the #1 killer of women in the U.S., many women are still unaware of the risk and the importance of heart health. The survey, endorsed by WomenHeart and conducted by Wakefield Research, found that nearly half of women (45%) were mor

      5/7/25 10:02:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic Affera™ pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients

      One-year clinical trial data for the next-generation, investigational, Sphere-360™ single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal AfibDual-energy (RF/PF), focal Sphere-9™ catheter demonstrates efficacy for linear ablation in persistent AFibMedtronic continues legacy of leadership in innovation, showcasing arrhythmia management portfolio at Heart Rhythm Society annual meetingGALWAY, Ireland and SAN DIEGO, April 26, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced positive clinical outcomes from two studies in atrial fibrillation (AFib) patients treated with the Affera™ family of techno

      4/26/25 7:20:00 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo™ robotic-assisted surgery system

      Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted urologic surgery in the U.S. presented as a late-breaker at the American Urologic Association annual meeting Company confirms Hugo RAS system submission to the U.S. Food and Drug Administration GALWAY, Ireland and LAS VEGAS, April 26, 2025 /PRNewswire/ -- Medtronic (NYSE:MDT), a global leader in healthcare technology, today announced that the Expand URO Investigational Device Exemption (IDE) clinical study, the largest such study for robotic-assisted urologic surgery ever conducted, met both primary safety and effectiveness endpoints. The prospective, multi-center, single-arm IDE stu

      4/26/25 2:20:00 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic receives FDA approval for smallest-diameter, lumenless defibrillation lead, the OmniaSecure™ lead and announces investigational clinical study results

      Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricle Heart Rhythm 2025: Late-breaking clinical study results evaluating the OmniaSecure lead for investigational use in the LBBAP location show high defibrillation success  GALWAY, Ireland and SAN DIEGO, April 25, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for the OmniaSecure™ defibrillation lead for placement within the right ventricle. The lead, built on the highly reliable SelectSecure™ Model 3830 pacing lead and delive

      4/25/25 5:45:00 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic advances Abbott CGM partnership with FDA submission of interoperable insulin pump

      GALWAY, Ireland, April 24, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has submitted 510(k) applications to the U.S. Food and Drug Administration (FDA) seeking clearance for an interoperable pump. FDA clearance of this pump would pave the way for system integration with a continuous glucose monitoring (CGM) sensor based on Abbott's most advanced CGM platform. The submissions included a 510(k) application for its MiniMed™ 780G pump as an alternate controller enabled (ACE) insulin pump and a separate 510(k) applicat

      4/24/25 9:00:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

      FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular riskHRS Satellite Symposium will feature leading experts in electrophysiology, hypertension management and heart failure Presentations will detail clinical results from prior studies demonstrating AVIM therapy's ability to immediately, substantially and persistently reduce systolic blood pressure, as well as improve cardiac functionSymposium will also feature presentation on the BACKBEAT global pivotal study Orchestra BioMed is currently enrolling in strategic collaboration with Medtronic, plc (NYSE:MDT) NEW HOPE, Pa., April 23, 2025 (GLOBE

      4/23/25 9:00:13 AM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products

    Medtronic plc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Chief HR Officer Walter Matthew R. covered exercise/tax liability with 34 units of Ordinary Shares, decreasing direct ownership by 0.13% to 26,054 units (SEC Form 4)

      4 - Medtronic plc (0001613103) (Issuer)

      5/5/25 4:10:23 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Accounting Officer Blomquist Denise L. was granted 2,975 units of Ordinary Shares, increasing direct ownership by 40% to 10,453 units (SEC Form 4)

      4 - Medtronic plc (0001613103) (Issuer)

      4/30/25 4:22:23 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Powell Kendall J was granted 2,083 units of Ordinary Shares and covered exercise/tax liability with 216 units of Ordinary Shares, increasing direct ownership by 4% to 48,622 units (SEC Form 4)

      4 - Medtronic plc (0001613103) (Issuer)

      4/30/25 4:21:33 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Nabel Elizabeth G was granted 2,083 units of Ordinary Shares and covered exercise/tax liability with 216 units of Ordinary Shares, increasing direct ownership by 12% to 17,615 units (SEC Form 4)

      4 - Medtronic plc (0001613103) (Issuer)

      4/30/25 4:20:27 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Lofton Kevin E was granted 2,083 units of Ordinary Shares and covered exercise/tax liability with 216 units of Ordinary Shares, increasing direct ownership by 30% to 8,171 units (SEC Form 4)

      4 - Medtronic plc (0001613103) (Issuer)

      4/30/25 4:19:08 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Lewis Gregory P was granted 2,083 units of Ordinary Shares and covered exercise/tax liability with 181 units of Ordinary Shares, increasing direct ownership by 101% to 3,785 units (SEC Form 4)

      4 - Medtronic plc (0001613103) (Issuer)

      4/30/25 4:18:07 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Hogan Randall J was granted 2,083 units of Ordinary Shares and covered exercise/tax liability with 216 units of Ordinary Shares, increasing direct ownership by 4% to 47,029 units (SEC Form 4)

      4 - Medtronic plc (0001613103) (Issuer)

      4/30/25 4:17:00 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Goldsmith Andrea Jo was granted 2,083 units of Ordinary Shares and covered exercise/tax liability with 216 units of Ordinary Shares, increasing direct ownership by 22% to 10,247 units (SEC Form 4)

      4 - Medtronic plc (0001613103) (Issuer)

      4/30/25 4:15:57 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Fonseca Lidia was granted 2,083 units of Ordinary Shares and covered exercise/tax liability with 216 units of Ordinary Shares, increasing direct ownership by 49% to 5,675 units (SEC Form 4)

      4 - Medtronic plc (0001613103) (Issuer)

      4/30/25 4:14:37 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Donnelly Scott C covered exercise/tax liability with 216 units of Ordinary Shares and was granted 2,083 units of Ordinary Shares, increasing direct ownership by 9% to 21,630 units (SEC Form 4)

      4 - Medtronic plc (0001613103) (Issuer)

      4/30/25 4:12:11 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Medtronic plc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Medtronic upgraded by Citigroup with a new price target

      Citigroup upgraded Medtronic from Neutral to Buy and set a new price target of $107.00 from $92.00 previously

      3/4/25 7:37:34 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded Medtronic from Sector Perform to Outperform and set a new price target of $105.00 from $98.00 previously

      10/10/24 7:57:15 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Oppenheimer reiterated coverage on Medtronic with a new price target

      Oppenheimer reiterated coverage of Medtronic with a rating of Perform and set a new price target of $94.00 from $92.00 previously

      8/21/24 7:55:37 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic upgraded by UBS with a new price target

      UBS upgraded Medtronic from Sell to Neutral and set a new price target of $90.00 from $76.00 previously

      8/15/24 7:32:47 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic downgraded by Stifel with a new price target

      Stifel downgraded Medtronic from Buy to Hold and set a new price target of $85.00 from $100.00 previously

      8/14/24 7:41:50 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Goldman initiated coverage on Medtronic with a new price target

      Goldman initiated coverage of Medtronic with a rating of Sell and set a new price target of $83.00

      5/30/24 7:56:37 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Robert W. Baird initiated coverage on Medtronic with a new price target

      Robert W. Baird initiated coverage of Medtronic with a rating of Neutral and set a new price target of $90.00

      7/19/23 7:18:39 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CL King initiated coverage on Medtronic with a new price target

      CL King initiated coverage of Medtronic with a rating of Buy and set a new price target of $106.00

      6/30/23 8:55:25 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Medtronic from Equal-Weight to Overweight and set a new price target of $104.00

      5/30/23 7:39:41 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Medtronic from Equal Weight to Overweight and set a new price target of $100.00 from $77.00 previously

      4/24/23 7:48:03 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Medtronic plc. SEC Filings

    See more
    • Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Medtronic plc (0001613103) (Filer)

      5/21/25 6:47:23 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic plc. filed SEC Form 8-K: Leadership Update

      8-K - Medtronic plc (0001613103) (Filer)

      3/17/25 4:30:48 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by Medtronic plc.

      10-Q - Medtronic plc (0001613103) (Filer)

      2/25/25 4:17:28 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Medtronic plc (0001613103) (Filer)

      2/18/25 6:46:40 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 144 filed by Medtronic plc.

      144 - Medtronic plc (0001613103) (Subject)

      1/24/25 2:34:15 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic plc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Medtronic plc (0001613103) (Filer)

      1/21/25 6:51:55 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 144 filed by Medtronic plc.

      144 - Medtronic plc (0001613103) (Subject)

      1/8/25 9:52:35 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by Medtronic plc.

      10-Q - Medtronic plc (0001613103) (Filer)

      11/26/24 4:16:06 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Medtronic plc (0001613103) (Filer)

      11/19/24 6:46:38 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 144 filed by Medtronic plc.

      144 - Medtronic plc (0001613103) (Subject)

      10/31/24 3:21:13 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Medtronic plc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

      SC 13G/A - Medtronic plc (0001613103) (Subject)

      2/13/24 5:09:43 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

      SC 13G/A - Medtronic plc (0001613103) (Subject)

      2/12/24 1:59:55 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

      SC 13G/A - Medtronic plc (0001613103) (Subject)

      2/15/23 3:34:14 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

      SC 13G/A - Medtronic plc (0001613103) (Subject)

      2/9/23 11:27:43 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

      SC 13G/A - Medtronic plc (0001613103) (Subject)

      2/10/22 8:27:59 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Medtronic plc

      SC 13G - Medtronic plc (0001613103) (Filed by)

      1/13/22 4:23:48 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Medtronic plc

      SC 13G - Medtronic plc (0001613103) (Filed by)

      5/3/21 9:32:20 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Medtronic plc (0001613103) (Subject)

      2/10/21 11:28:18 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Medtronic plc (0001613103) (Subject)

      2/3/21 1:13:21 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Medtronic plc. Financials

    Live finance-specific insights

    See more
    • Medtronic announces cash dividend for fourth quarter of fiscal year 2025

      GALWAY, Ireland, March 6, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 6, 2025, approved the company's cash dividend for the fourth quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on April 11, 2025, to shareholders of record at the close of business on March 28, 2025. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquart

      3/6/25 4:30:00 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic reports third quarter fiscal 2025 financial results

      Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation GALWAY, Ireland, Feb. 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025. Key Highlights Revenue of $8.3 billion increased 2.5% as reported and 4.1% organicGAAP diluted EPS of $1.01 increased 2%; non-GAAP diluted EPS of $1.39 increased 7%Company reiterates full year revenue and EPS guidanceCardiac Ablation Solutions revenue increased low-20s on strength of pulsed field ablation (PFA) productsU.S. Centers for Medicare and Medic

      2/18/25 6:45:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic announces cash dividend for third quarter of fiscal year 2025

      GALWAY, Ireland, Dec. 5, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 5, 2024, approved the company's cash dividend for the third quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on January 10, 2025, to shareholders of record at the close of business on December 27, 2024. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, hea

      12/5/24 4:30:00 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic reports second quarter fiscal 2025 financial results

      Delivering on commitments, executing ahead of expectations, and raising guidance Innovation driving sustained growth across many franchises:  TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and Neuromodulation GALWAY, Ireland, Nov. 19, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its second quarter (Q2) of fiscal year 2025 (FY25), which ended October 25, 2024. Key Highlights Revenue of $8.4 billion increased 5.3% as reported and 5.0% organicGAAP diluted earnings per share (EPS) of $0.99; non-GAAP diluted EPS of $1.26Company raises FY25 organic revenue growth and EPS guidanceFinancial ResultsMedtronic reported Q2 worldwide revenue of $8.403 billion, an

      11/19/24 6:45:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • PaceMate® Acquires Medtronic Paceart Optima™ System, Bringing Complementary Capabilities to Cardiac Data Management

      PaceMate®, a pioneer in cardiac data management and remote monitoring, announced today the acquisition of the Paceart Optima™ system, an on-premises cardiac workflow solution from Medtronic (NYSE:MDT) This strategic move significantly expands PaceMate's reach globally, adding nearly 1,000 clinic locations worldwide. This further enhances PaceMate's ability to provide the leading and most comprehensive cardiac remote monitoring solution, continuing its position as the preferred partner in advanced cardiac data management. "After a comprehensive evaluation, we are confident PaceMate is the best organization to service Paceart customers and their future cardiac data workflow needs," said Kwe

      8/27/24 8:00:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic reports first quarter fiscal 2025 financial results

      Product innovation driving growth across diversified health tech portfolio, including Automated Insulin Delivery, Transcatheter Aortic Valve Replacement, Pulsed Field Cardiac Ablation, Pain Stimulation, and Deep Brain Stimulation GALWAY, Ireland, Aug. 20, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its first quarter (Q1) of fiscal year 2025 (FY25), which ended July 26, 2024. Key Highlights Revenue of $7.9 billion, adjusted revenue of $8.0 billion, increased 2.8% as reported and 5.3% organicGAAP diluted earnings per share (EPS) of $0.80; non-GAAP diluted EPS of $1.23Company increases FY25 organic revenue growth and EPS guidanceMultiple franchises deliv

      8/20/24 6:45:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic announces cash dividend for second quarter of fiscal year 2025

      GALWAY, Ireland, Aug. 16, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 15, 2024, approved the company's cash dividend for the second quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on October 11, 2024, to shareholders of record at the close of business on September 27, 2024. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, h

      8/16/24 7:00:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic reports full year and fourth quarter fiscal 2024 financial results; announces dividend increase

      Broad-based, durable growth across the company, including Cranial & Spinal Technologies, Diabetes, Cardiac Pacing, Surgical, and Structural Heart; gaining momentum as company enters new product cycles across many high-growth markets DUBLIN, May 23, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter (Q4) and fiscal year 2024 (FY24), which ended April 26, 2024. Key Highlights Q4 revenue of $8.6 billion increased 0.5% as reported and 5.4% organicQ4 GAAP diluted earnings per share (EPS) of $0.49; non-GAAP diluted EPS of $1.46FY24 revenue of $32.4 billion increased 3.6% as reported and 5.2% organicFY24 GAAP diluted EPS of $2.76; non-GAAP dilute

      5/23/24 6:45:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic announces cash dividend for fourth quarter of fiscal year 2024

      Board authorizes $5 billion for share repurchases DUBLIN, March 7, 2024  /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 7, 2024, approved the company's cash dividend for the fourth quarter of fiscal year 2024 of $0.69 per ordinary share. This quarterly declaration is consistent with the dividend announcement made by the company in May 2023.  Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 46 consecutive years. The dividend is payable on April 12, 2024, to shareholders of record at the close of business on March 22, 2024. In addition to approving the dividend, the board today

      3/7/24 4:20:00 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic reports third quarter fiscal 2024 financial results

      Delivers on commitments with strong growth in Core Spine, Cardiac Surgery, Structural Heart, Cardiac Pacing, and across many international markets; Diabetes increases double digits as U.S. business returns to growth; Raises full year guidance DUBLIN, Feb. 20, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its third quarter (Q3) of fiscal year 2024 (FY24), which ended January 26, 2024. Key Highlights Revenue of $8.1 billion increased 4.7% as reported and 4.6% organicGAAP diluted earnings per share (EPS) of $0.99; non-GAAP diluted EPS of $1.30Raises FY24 organic revenue growth and EPS guidanceCompany provides portfolio management update on Patient Monitori

      2/20/24 6:45:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Medtronic plc. Leadership Updates

    Live Leadership Updates

    See more
    • Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

      NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

      3/31/25 4:21:30 PM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products
    • Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

      Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development ("R&D") collaborations aligned with Orchestra BioMed's partnership-enabled business model Mr. Cleary previously served as Senior Vice President ("SVP") of Corporate Development at Medtronic plc (NYSE:MDT) ("Medtronic"), where he played a key role in establishing the strategic collaboration between Orchestra BioMed and Medtronic for atrioventricular interval modulation ("AVIM") therapy in hypertension with increased cardiovascular riskEric A. Rose, M.D. to transition from Board Member to Board Member Emeritus and Strategic Advisor, continuing to provide invaluable expe

      2/5/25 8:00:00 AM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products
    • Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

      2/3/25 4:00:00 PM ET
      $INGN
      $MDT
      $MYO
      Industrial Specialties
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Medtronic appoints Thierry Piéton as Chief Financial Officer

      GALWAY, Ireland, Jan. 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that Thierry Piéton has been appointed Chief Financial Officer for the company, effective March 3, 2025. He will report to Medtronic Chairman and Chief Executive Officer Geoff Martha and will join the Medtronic Executive Committee. Piéton joins Medtronic from Renault Group, where he has served as Chief Financial Officer since March 2022. Gary Corona, who has been serving as interim CFO, will continue in this role until Piéton joins Medtronic, after which Corona will become Senior Vice President, Corporate Finance and will remain on the Medtronic Executive Commit

      1/21/25 6:50:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Sempra Appoints Jennifer M. Kirk to Board of Directors

      SAN DIEGO, June 20, 2024 /PRNewswire/ -- Sempra (NYSE:SRE) (BMV:SRE) today announced the appointment of Jennifer M. Kirk to the company's board of directors effective June 20, 2024. Kirk is currently the global controller and chief accounting officer of Medtronic plc (NYSE:MDT) and has deep executive experience in finance, accounting and capital market activities, including more than 20 years in the energy industry. "Bringing new perspectives into the boardroom is a critical component of our effort to support the company's mission to build North America's premier energy infras

      6/20/24 4:15:00 PM ET
      $MDT
      $SRE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Natural Gas Distribution
      Utilities
    • Gentherm Announces Dr. Ken Washington as New Independent Director

      NORTHVILLE, Mich., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM), the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical patient temperature management systems, today announced that Dr. Ken Washington has been appointed to the Company's Board of Directors, effective October 2, 2023. Dr. Washington is the Senior Vice President, Chief Technology and Innovation Officer of Medtronic plc (NYSE:MDT), a global healthcare technology company that provides device-based medical therapies and services. He was appointed to this position in June 2023, and he leads innovation and the expansion of technol

      10/2/23 8:00:00 AM ET
      $AMZN
      $F
      $MCK
      $MDT
      Catalog/Specialty Distribution
      Consumer Discretionary
      Auto Manufacturing
      Other Pharmaceuticals
    • Medtronic Board appoints Greg Lewis as new Director

      DUBLIN, June 26, 2023 /PRNewswire/ -- Medtronic announced today that its Board of Directors appointed Greg Lewis, Senior Vice President and Chief Financial Officer at Honeywell, to the Board. Lewis will serve on the Audit Committee and the Finance and Financial Risk Committee, effective June 26, 2023. "We are thrilled to have Greg Lewis join our Board. His background in financial leadership across multiple industries will be a strong asset as Medtronic pushes forward a comprehensive transformation that will set us up to deliver on durable growth," said Geoff Martha, Chairman and CEO of Medtronic. "I'm honored to join the Medtronic Board of Directors. I believe in the company's mission to al

      6/26/23 7:00:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors

      Recently Retired Medtronic Chief Medical Officer and Chief Scientific Officer with Deep Expertise in Stroke Treatment DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023. Dr. Richard Kuntz recently retired from Medtronic plc (NYSE:MDT) where he was the Chief Medical Officer & Scientific Officer and a member of the Executive Committee. Prior to that, he served as Senior Vice President and President, Neuromodulation of Medtronic from October 2005 to August 2009. Before joining Medtronic, he was

      5/30/23 8:29:00 AM ET
      $DMAC
      $MDT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Medtronic Board appoints Lidia Fonseca as a new director

      DUBLIN, June 27, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced that its Board of Directors appointed Lidia Fonseca, Executive Vice President, Chief Digital and Technology Officer at Pfizer, to the Board as an independent director, effective June 27, 2022. Ms. Fonseca will serve on the Compensation Committee and Science and Technology Committee of the Board. "We are thrilled to welcome Lidia to Medtronic's Board of Directors," said Geoff Martha, Medtronic chairman and chief executive officer. "She has an impressive history of developing digital healthcare solutions that deliver powerful insights to improve patients' lives. Her extensive knowledge and expertise will provide the

      6/27/22 7:00:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic appoints new Operating Unit Presidents

      Que Dallara joins as EVP & President, Diabetes Mike Marinaro named President, Surgical Robotics Dr. Kweli Thompson named President, Cardiac Rhythm Management DUBLIN, March 17, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced leadership transitions for three of its Operating Units – Diabetes, Surgical Robotics, and Cardiac Rhythm Management – bringing in critical skills and capabilities and creating opportunities for internal talent. "The future of medical technology requires strong leadership in data science, artificial intelligence, and robotics, all of which make these three Operating Unit President roles some of the most important a

      3/17/22 8:30:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care